Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
NeoAPBI 01: Sequential APBI and Chemotherapy vs Chemotherapy Alone in Breast Cancer
NCT02806258Phase 2Terminated
- Sponsor
- CHU Grenoble Alpes
- Start
- Apr 2016
- Primary completion
- May 2024
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial in breast cancer (2 arms), sponsored by CHU Grenoble Alpes. Primary endpoint: Pathological Complete Response at 21 weeks. Started Apr 2016; status: terminated.
02
Conditions
breast cancer
Beyond the preview
Go deeper on NCT02806258.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02806258.